期刊文献+

莫西沙星注射液治疗重症社区获得性肺炎疗效观察 被引量:1

Effect of moxifloxacin on severe community acquired pneumonia
原文传递
导出
摘要 目的观察莫西沙星注射液治疗重症社区获得性肺炎的临床疗效。方法将符合入选条件的60例重症社区获得性肺炎患者分为治疗组和对照组,每组30例,两组基础治疗相似,治疗组患者予莫西沙星注射液250ml,静脉点滴,每天1次,共6d;对照组30例,予注射用头孢曲松钠2.0g加入0.9%氯化钠注射液250 mL,静脉点滴,每天1次,共6d。6d后,根据病情决定是否继续进行抗生素治疗。分别给予治疗前后临床疗效比较,同时检测治疗前、后的血常规及痰培养等。结果治疗组疗效(80%)明显优于对照组(60%),差异有统计学意义(P<0.05),且无不良反应。结论莫西沙星注射液治疗重症社区获得性肺炎疗效确切,安全可靠。 Objective To observe the curative effect of moxifloxacin injection on severe community acquired pneumonia.Methods Sixty cases with severe community acquired pneumonia were selected based on the diagnositic criteria and radomly divided into treatment group and control group each consisted of 30 cases.Patients in the treatment group were given moxifloxacin injection 250ml by IV drip,1/day,for 6 days;Those in the control group received ceftriaxone sodium for injection 2g in250mL0.9% sodium chloride injection vy IV drip,1/day,for 6 days.Then routine blood examination and sputum culture were conduceted and the clinical efficacy in both groups were compared before and after treatment.Results The effictive rate in the treatment group was 80% higher than that of the control group(60%),showing significant difference(P0.05)without adverse reaction.Conclusion The curative effect of moxifloxacin injection in the treatment of severe community acquired pneumonia is accurate,safe and reliable.
出处 《中国热带医学》 CAS 2012年第4期517-518,共2页 China Tropical Medicine
关键词 重症社区获得性肺炎 莫西沙星 疗效 Severe community acquired pneumonia Moxifloxacin Curative effect
  • 相关文献

参考文献7

二级参考文献41

  • 1沈定霞,罗燕萍,崔岩,赵莉萍,白立彦.分离产金属β-内酰胺酶的铜绿假单胞菌[J].中华医院感染学杂志,2004,14(1):86-88. 被引量:109
  • 2王鋆,张钧.药物经济学成本-效果分析[J].药学实践杂志,1995,13(4):193-197. 被引量:462
  • 3刘又宁,陈民钧,赵铁梅,王辉,王睿,刘庆锋,蔡柏蔷,曹彬,孙铁英,胡云建,修清玉,周新,丁星,杨岚,卓建生,唐英春,张扣兴,梁德荣,吕晓菊,李胜歧,刘勇,俞云松,魏泽庆,应可净,赵峰,陈萍,侯晓娜.中国城市成人社区获得性肺炎665例病原学多中心调查[J].中华结核和呼吸杂志,2006,29(1):3-8. 被引量:788
  • 4周淑新,杨爱芳.社区获得性肺炎的诊断与治疗[J].中国全科医学,2006,9(9):725-727. 被引量:5
  • 5Ngeow YF,Suwanjutha S,Chantarojanasriri T,et al.An Asian study on the prevalence of atypical respiratory pathogens in community-acquired pneumonia.Int J Infect Dis,2005,9:144-153.
  • 6de Roux A,Marcos MA,Garcia E,et al.Viral community-acquired pneumonia in nonimmunocompromised adults.Chest,2004,125:1343-1351.
  • 7Ostrosky-Zeichner L,Alexander BD,Kett DH,et al.Multicenter clinical evaluation of the (1→3) beta-D-glucan assay as an aid to diagnosis of fungal infections in humans.Clin Infect Dis,2005,41:654-659.
  • 8Food and Drug Administration,HHS.Class Ⅱ Special Controls Guidance Document:serological assays for the detection of betaglucan.Fed Reqist,2004,69:56934-56936.
  • 9Mandell LA,Marrie TJ,Grossman RF,et al.Canadian guidelines for the initial management of community-acquired pneumonia:an evidence-based update by the Canadian Infectious Diseases Society and the Canadian Thoracic Society.The Canadian CommunityAcquired Pneumonia Working Group.Clin Infect Dis,2000,31:383-421.
  • 10Woodhead M,Blasi F,Ewig S,et al.Guidelines for the management of adult lower respiratory tract infections.Eur Respir J,2005,26:1138-1180.

共引文献3064

同被引文献11

引证文献1

二级引证文献13

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部